预约演示
Lyell loses 25% of staff, CMO as biotech conserves funding to survive in post-GSK future
2023-11-08
细胞疗法临床1期免疫疗法基因疗法
Chief Medical Officer Tina Albertson, M.D., Ph.D., is departing Lyell Immunopharma.
A year after Lyell Immunopharma lost a $1 billion biobucks partnLyell Immunopharmahe cell therapy biotech is offloading a quarter of its staff and deprioritizing some earlier-stage research to extend funding into 2027.
The company iLyell Immunopharmag investment in its most value enhancing clinGSKl-stage product candidates and core research platforms,” Lyell explained in a third-quarter earning release Tuesday. Leading the charge is a ROR1-targeted CAR-T dubbed LYL797, which is undergoing a phase 1 trial in patients with relapsed or refractory triple-negative breast cancer or non-small cell lung cancer (NSCLC). A readout from the first 20 patients enrolled in the study is expected in the first half of next year.
Lyell’s other clinical-stage asset is LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocyte (TIL) product being assessed in patients with relapsed and/or refractory metastatic or locally advanced melanoma,ROR1-targetedlorectal canceLYL797relapsed or refractory triple-negative breast cancernon-small cell lung cancer (NSCLC)
Lyelliotech will also persevere with tLYL845clinical candidates: another ROR1tumoreted CAR-T called LYL119 and a second-generation TIL.relapsed and/or refractory metastatic or locally advanced melanomaNSCLCcolorectal cancer
Meanwhile, the company has “scaled down investment in certain early-stageROR1-targetedgCAR-Tand stage gated certain other expenses.” This has resulted in a 25% reduction in the biotech’s workforce, which is expected to be completed before the end of the year. Chief Medical Officer Tina Albertson, M.D., Ph.D., is also departing the business.
Explaining the restructuring, CEO Lynn Seely, M.D., said the company “remains confident in our science, our product candidates and our ability to deliver meaningful advances in cell therapy to patients with solid tumors.”
“We are focused on strengthening our ability to fully elucidate the potential of the currently disclosed product candidates in our pipeline through multiple clinical milestones and have extended our ability solid tumorsations into 2027,” Albertson added in the release. “We have restructured our company to prioritize investment in our clinical stage programs and core research platforms and have streamlined operations.”
The downsizing means that Lyell now expects the $598.2 million it has in cash and equivalents to fund its clinical programs for at least three more years. That breathing space might start to come in useful soon, as the biotech comes to terms with the loss of potentially $1 billion in milestones from its GSK collaboration.
Lyell partnered with the BLyellh Big Pharma in 2019, securing $45 million upfront to apply its technologies to T-cell therapies. But, by summer 2022, Lyell was warning that the partnership faced “new uncertainty” because GSK had stopped enrollment in a clinical trial of a first-generation NY-ESO-1 candidGSK after it delivered lackluster data.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。